233 related articles for article (PubMed ID: 23969999)
1. Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin.
Chekhun VF; Lukyanova NY; Burlaka CA; Bezdenezhnykh NA; Shpyleva SI; Tryndyak VP; Beland FA; Pogribny IP
Int J Oncol; 2013 Nov; 43(5):1481-6. PubMed ID: 23969999
[TBL] [Abstract][Full Text] [Related]
2. Artemisinin modulating effect on human breast cancer cell lines with different sensitivity to cytostatics.
Chekhun VF; Lukianova NY; Borikun TV; Zadvorny TV; Mokhir A
Exp Oncol; 2017 Mar; 39(1):25-29. PubMed ID: 28361857
[TBL] [Abstract][Full Text] [Related]
3. Role of ferritin alterations in human breast cancer cells.
Shpyleva SI; Tryndyak VP; Kovalchuk O; Starlard-Davenport A; Chekhun VF; Beland FA; Pogribny IP
Breast Cancer Res Treat; 2011 Feb; 126(1):63-71. PubMed ID: 20390345
[TBL] [Abstract][Full Text] [Related]
4. Cytoprotective effects of ferritin on doxorubicin-induced breast cancer cell death.
Buranrat B; Connor JR
Oncol Rep; 2015 Nov; 34(5):2790-6. PubMed ID: 26352101
[TBL] [Abstract][Full Text] [Related]
5. The lipid content of cisplatin- and doxorubicin-resistant MCF-7 human breast cancer cells.
Todor IN; Lukyanova NY; Chekhun VF
Exp Oncol; 2012 Jul; 34(2):97-100. PubMed ID: 23013760
[TBL] [Abstract][Full Text] [Related]
6. Modulation of intracellular iron metabolism by iron chelation affects chromatin remodeling proteins and corresponding epigenetic modifications in breast cancer cells and increases their sensitivity to chemotherapeutic agents.
Pogribny IP; Tryndyak VP; Pogribna M; Shpyleva S; Surratt G; Gamboa da Costa G; Beland FA
Int J Oncol; 2013 May; 42(5):1822-32. PubMed ID: 23483119
[TBL] [Abstract][Full Text] [Related]
7. Effect of 5-azacytidine on miRNA expression in human breast cancer cells with different sensitivity to cytostatics.
Chekhun VF; Borikun TV; Lukianova NY
Exp Oncol; 2016 Mar; 38(1):26-30. PubMed ID: 27031715
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
9. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin.
Pogribny IP; Filkowski JN; Tryndyak VP; Golubov A; Shpyleva SI; Kovalchuk O
Int J Cancer; 2010 Oct; 127(8):1785-94. PubMed ID: 20099276
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.
Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D
J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response.
Zhong Y; Zhang F; Sun Z; Zhou W; Li ZY; You QD; Guo QL; Hu R
Mol Carcinog; 2013 Oct; 52(10):824-34. PubMed ID: 22593043
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12.
Thomadaki H; Scorilas A
Ann N Y Acad Sci; 2007 Jan; 1095():35-44. PubMed ID: 17404015
[TBL] [Abstract][Full Text] [Related]
13. Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin.
Lukyanova NY; Rusetskya NV; Tregubova NA; Chekhun VF
Exp Oncol; 2009 Jun; 31(2):87-91. PubMed ID: 19550397
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
Ogretmen B; McCauley MD; Safa AR
Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
[TBL] [Abstract][Full Text] [Related]
15. Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer.
He DX; Gu XT; Li YR; Jiang L; Jin J; Ma X
FEBS J; 2014 Oct; 281(20):4718-30. PubMed ID: 25156775
[TBL] [Abstract][Full Text] [Related]
16. Resistance to cisplatin and adriamycin is associated with the inhibition of glutathione efflux in MCF-7-derived cells.
Osbild S; Brault L; Battaglia E; Bagrel D
Anticancer Res; 2006; 26(5A):3595-600. PubMed ID: 17094488
[TBL] [Abstract][Full Text] [Related]
17. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production.
Shi Z; Yang WM; Chen LP; Yang DH; Zhou Q; Zhu J; Chen JJ; Huang RC; Chen ZS; Huang RP
Breast Cancer Res Treat; 2012 Oct; 135(3):737-47. PubMed ID: 22923236
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets.
Chekhun VF; Lukyanova NY; Kovalchuk O; Tryndyak VP; Pogribny IP
Mol Cancer Ther; 2007 Mar; 6(3):1089-98. PubMed ID: 17363502
[TBL] [Abstract][Full Text] [Related]
19. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of human breast carcinoma MCF-7 cells differing in their resistance to doxorubicin: effect of ionizing radiation on apoptosis and TGF-beta production.
Chorna I; Bilyy R; Datsyuk L; Stoika R
Exp Oncol; 2004 Jun; 26(2):111-7. PubMed ID: 15273662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
